OBJECTIVES: To examine the methodological quality of drug safety systematic reviews, and to investigate factors associated with the methodological quality of drug safety systematic review by conducting a cross-sectional survey. METHODS:
We searched PubMed to identity published in the Cochrane Database of Systematic Reviews and Core Clinical Journals indexed in 2015, and randomly sampled the studies with 1:1 of Cochrane and non-Cochrane systematic reviews regarding drug safety. We used the AMSTAR tool to assess the methodological quality of included studies. Multivariable linear regression analyses were used to assess the association between the seven specified variables with AMSTAR score. RESULTS: We included 120 systematic reviews, including 60 Cochrane systematic reviews and 60 non-Cochrane systematic reviews. The mean (standard deviation) overall score for the AMSTAR tool (11 items) in Cochrane systematic reviews was higher than in non-Cochrane systematic reviews (10±0.9 vs. 8.67±0.95; P<0.001). Multivariable linear regression analyses showed that type of systematic review (P<0.001) and area of diseases (P= 0.01) were the factors associated with the methodological quality. CONCLUSIONS: Our study showed that Cochrane systematic reviews had better methodological quality than non-Cochrane systematic reviews. Type of systematic review and area of diseases were the factor associated with the reporting and methodological quality, and the methodological quality of non-Cochrane systematic review should be improved in the future.
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REPORTING QUALITY OF DRUG SAFETY SYSTEMATIC REVIEWS: A CROSS-SECTIONAL STUDY
Li L 1 , Xu C 1 , Deng K 1 , Zhou X 2 , Sun X 1 1 West China Hospital, Sichuan University, Chengdu, China, 2 Jiangxi University of Traditional Chinese Medicine, Nanchang, China OBJECTIVES: To examine the reporting quality of drug safety systematic reviews, and to investigate factors associated with the reporting quality by conducting a cross-sectional survey. METHODS: We searched PubMed to identity published in the Cochrane Database of Systematic Reviews and Core Clinical Journals indexed in 2015, and randomly sampled the studies with 1:1 of Cochrane and non-Cochrane systematic reviews regarding drug safety. We used PRISMA and PRISMA harms checklist to assess the reporting quality. Multivariable linear regression analyses were used to assess the association between the seven specified variables with PRISMA and PRISMA harms scores. RESULTS: We included 120 systematic reviews, including 60 Cochrane and 60 non-Cochrane systematic reviews. The mean (standard deviation, SD) overall score for the PRISMA checklist (27 items) in Cochrane systematic reviews was higher than in non-Cochrane systematic reviews (24.8±2.1 vs. 23.1±2.6; P<0.001). The mean (SD) overall score for the PRISMA harms checklist (24 items) were low both in Cochrane and non-Cochrane systematic reviews, and there was no statistical difference between these two type of reviews (4.4±2.5 vs. 3.9±2.4; P<0.27). The mean (SD) overall score for the PRISMA and PRISMA harms checklist (total 51 items) in Cochrane systematic reviews was higher than in non-Cochrane reviews (29.2±3.0 vs. 27.0±4.3;P= 0.002). Multivariable linear regression analyses showed that type of systematic review (P= 0.003) and type of journal (P= 0.04) were the factors associated with the total reporting quality. CONCLUSIONS: Our study showed that both Cochrane and non-Cochrane systematic reviews had good reporting in PRISMA, and Cochrane systematic reviews had better reporting quality than non-Cochrane systematic reviews. However, both these two types of reviews had poor reporting in PRISMA harms. Type of systematic review and type of journal were the factors associated with the reporting quality, and the reporting quality of non-Cochrane systematic reviews in PRISMA harms should be improved in the future.
MULTIPLE DISEASES -Cost Studies
PMU17 ADDITIONAL BENEFIT SCORING DURING HEALTH TECHNOLOGY ASSESSMENT IN GERMANY -ITS DRIVERS AND IMPACT ON PRICING AND DISCOUNT FOR ORPHAN DRUGS
Oku Y 1 , Fukushima A 2 , Dorey J 2 , Toumi M 3 1 Kyoto University, Kyoto, Japan, 2 Creativ-Ceutical, Paris, France, 3 Aix Marseille University,
Marseille, France
OBJECTIVES: To identify the drivers of additional benefit scoring during health technology assessment (HTA) of orphan drugs (ODs) and assess the relationship between HTA score and drug price or discount rate in Germany. METHODS: ODs then coronary disease (16%). Comorbidity rates were not significantly different year on year. Yearly medical costs associated with comorbidities were also higher. Statin users with coronary disease presented higher costs (3,890,531 KRW) followed by DM (2,890,531 KRW) and muscle pain (2,753,612 KRW) compared to those without comorbidities (2, 442, 358 KRW) . CONCLUSIONS: Prevalence of statin users increased significantly year on year, and higher medical costs were observed for those with comorbidities. The results suggest that better disease management of statin users with comorbidities may be warranted. Given the increasing prevalence and economic burden, improved treatments for these groups may yield substantial cost savings.
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EFFECTS OF TURMERIC ON CLINICAL CONDITIONS: UMBRELLA REVIEWS OF SYSTEMATIC REVIEW AND META-ANALYSIS Toonmala K 1 , Chaiyasitthipoonpong M 1 , Phianchana P 1 , Chaiyakunapruk N 2 , Sawangjit R 1 1 Mahasarakham University, Maha Sarakham, Thailand, 2 Naresuan University, Phitsanulok, Thailand OBJECTIVES: To perform umbrella review of systematic reviews and metaanalysis (SR-MA) investigating effects of Turmeric on any clinical condition in human. METHODS: PUBMED, AMED, EMBASE, and Cochrane Library were searched from inception till December 2017. AMSTAR2 was used to evaluate quality of included studies. We estimated the effect size by using random-effects and fixed-effects models, the 95%Confidence and prediction intervals. The heterogeneity between studies was assessed by I2 (defined as large for I² ≥ 50%). The small study effects were assessed by funnel plot asymmetry and Egger's regression test. Whenever more than one SR-MA had been performed on the same clinical condition, we included the one with the largest number of primary studies to avoid duplication. The evidence was graded into convincing, suggestive, or weak. RESULTS: Overall, 22 SR-MA with 53 unique meta-analyses (MA) with moderate-high methodological quality were included. The effects of Turmeric on a wide range of clinical conditions were determined including musculoskeletal pain, joint arthritis, depression, anxiety, Alzheimer, potentially malignant disorders, oral lichen planus, ulcerative colitis, Crohn's disease, diabetes, metabolic syndrome/dyslipidemia/obesity, uremic pruritus in hemodialysis patients, and skin disorders (acne, facial photoaging, eczema, androgenic alopecia, psoriasis, vitiligo, radio-protective in head-neck, and breast cancer). Among these, Turmeric significant improved health outcomes of knee OA, depression, and metabolic syndrome or dyslipidemia with p-value< 0.001 (I²< 50%, no small-study effects). Other conditions, except anxiety, Alzheimer, oral lichen planus, androgenic alopecia, and vitiligo were significant improved by Turmeric with p-value< 0.05. Since all MA evaluating patients less than 1000 and 95%PI including the null value, evidence grading was weak. CONCLUSIONS: Although Turmeric effects showed benefit in several clinical conditions, small sample size limited the quality of evidence. Further large trials need to confirm the benefit of Turmeric on these conditions.
PMU11 THE RELATIONSHIP BETWEEN SOCIO ECONOMIC STATUS AND TRAUMATIC BRAIN INJURIES FOR PEDIATRIC POPULATIONS
Friger M 1 , Schuurman N 2 , Amram O 3 1 Ben-Gurion University, Beer Sheva, Israel, 2 Simon Fraser University, Burnaby, BC, Canada, 3 Washington State University, Spokane, WA, USA OBJECTIVES: For children fourteen years old or younger, injuries are the main cause of death and one of the principal causes of morbidity in Canada. Low Socio-Economic Status (SES) appears to be correlated to a higher incidence of injuries. The main objective of this study is to determine the presence of pediatric Traumatic Brain Injuries (TBI) hotspots by analyzing the correlation of SES and TBI rates in Greater Vancouver, BC, Canada. METHODS: We identified all pediatric TBI patients hospitalized in BC between 2000 and 2013 by using pediatric Traumatic Brain Injury data obtained from the BC Trauma Registry. Pediatric TBI hotspots were identified through the utilization of spatial analysis techniques. Census variables correlated to rates of injury were assessed by employing a multivariate negative binomial regression. RESULTS: In BC's Lower Mainland, a total of six hundred and fifty-three severe pediatric TBI injuries were recorded between 2000 and 2013. 335 cases involved injury severity scores (ISS) ≥ 25, while the rest were defined as moderately severe. The eastern areas, characterized by a lower SES, showed the highest injury rates, while the western areas, consisting of more affluent households, mainly showed low rates clusters. The final model results showed statistically significant that a 10% increase in the ratio of people without a high school diploma corresponded to a 13% increase of injury rates. CONCLUSIONS: Income based indicators appear to be unreliable predictors in Greater Vancouver, despite the clear correlation of SES and pediatric TBI rates in this region.
PMU12
STEWARDSHIP OF MEDICATION ERRORS IN A DEVELOPING COUNTRY'S SCENARIO: A CLINICAL PHARMACIST'S ROLE
Chalasani SH 1 , Ramesh M 2 1 JSS College of Pharmacy, Mysuru, India, 2 JSS College of Pharmacy, JSS University, Mysore, India, Mysore, India OBJECTIVES: To establish medication error reporting and monitoring programme in a tertiary care teaching hospital. METHODS: A prospective cohort study was conducted among patients aged ≥ 18 years hospitalised in a south Indian hospital over three years. On a daily basis, patients, patient's caregivers, and health care professionals (HCPs) were interviewed about the medication use process and patients' notes reviewed for identifying and evaluating outcomes of ME using the NCC MERP and Prevention standards. Root cause analysis was performed to understand the reasons and discussed with the relevant HCP to minimise the likelihood of recurrence of the ME. RESULTS: A total of 1310 medication errors were reported among 20256 patients hospitalised and the incidences 6.4%. Aetiologies of reported MEs were administration errors 501(38.2%), prescribing and transcribing errors total-
